MedTrace Logo

Observational Post-Authorisation Safety Study of Asenapine (Sycrest)

NCT01734278 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2018-07-31

No results posted yet for this study

Summary

The purpose of this observational study is to evaluate the use and short term safety of Asenapine (Sycrest) in real-life usage in the Mental Health Trust Setting in the United Kingdom(UK) National Health Service (NHS). The study is to be carried out independently by the Drug Safety Research Unit (DSRU) in Southampton, although it is funded by Merck, the manufacturer of Sycrest.

Conditions

  • Manic Disorder

Interventions

OTHER

No intervention

This is a non-interventional study.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2017-01-31
Completion
2018-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01734278 on ClinicalTrials.gov